leishmaniasis program (DNDi/WuXi AppTech/TCG Life Sciences/University of Antwerp/London School of Hygiene and Tropical Medicine/Epichem/Centre for Drug Candidate Optimisation/Griffiths University/GSK/Sanofi)

N/A

Report date: 2025/06/11 10:30:33
NME

Base Information

Drug Nameleishmaniasis program (DNDi/WuXi AppTech/TCG Life Sciences/University of Antwerp/London School of Hygiene and Tropical Medicine/Epichem/Centre for Drug Candidate Optimisation/Griffiths University/GSK/Sanofi)
Drug Alias NameN/A
ClassificationSmall molecules
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsLeishmania donovani infection
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesDrugs For Neglected Diseases Initiative
China Registration ClassN/A

Develop Information

Active CompaniesEpichem Group LtdCentre for Drug Candidate OptimisationGriffith University +[10] 
Inactive CompaniesN/A
Active IndicationsLeishmania donovani infection
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A